| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 154, Issue 6 2794-2800, Copyright © 1995 by American Association of Immunologists
ARTICLES |
G Yang, KE Hellstrom, I Hellstrom and L Chen
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121.
We have examined the role of the B7-2 costimulatory molecule, a second ligand for CD28/CTLA-4 counter-receptors, in the induction of antitumor immunity. A plasmid containing murine B7-2 cDNA was transfected into the immunogenic mouse mastocytoma P815 of DBA/2 origin. In contrast to the lethal growth of the wild-type (wt) P815 tumor, B7-2-positive (B7- 2+) P815 cells inoculated into syngeneic mice regressed, and immunization of mice with such tumor cells protected them against the challenge of wt P815 tumor. Depletion of CD8+, but not of CD4+, lymphocytes in vivo by specific Abs abolished the regression of B7-2+ P815 tumors. CD8+ cytolytic T cells could be generated from mice immunized with B7-2+ P815. They were found to be MHC class I-restricted and specific for the P815 tumor. In contrast, transfection of the B7-2 gene into the nonimmunogenic MCA102 fibrosarcoma of C57BL/6 origin induced neither tumor regression nor protective immunity. Co-expression on MCA102 cells of B7-2 together with the related costimulator B7-1 also failed to induce immunity to MCA102 tumor. Our results indicate that transfection of B7-2 into tumor cells can improve host response to some tumors, and that the effects seen are similar to those previously observed for B7-1.
This article has been cited by other articles:
|
|
 |
|
  I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, et al. Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma Cancer Res., February 15, 2006; 66(4): 2442 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Dolan, K. D. Gibbs Jr., and S. Ostrand-Rosenberg Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines J. Immunol., February 1, 2006; 176(3): 1447 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tamura, K. Dan, K. Tamada, K. Nakamura, Y. Shioi, H. Hyodo, S.-D. Wang, H. Dong, L. Chen, and K. Ogata Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia Clin. Cancer Res., August 15, 2005; 11(16): 5708 - 5717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Pappu and P. A. Shrikant Alteration of Cell Surface Sialylation Regulates Antigen-Induced Naive CD8+ T Cell Responses J. Immunol., July 1, 2004; 173(1): 275 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. A. Van Ginderachter, L. Brys, P. De Baetselier, G. Raes, and A. B. Geldhof Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells J. Immunol., May 15, 2003; 170(10): 5064 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tamura, H. Dong, G. Zhu, G. L. Sica, D. B. Flies, K. Tamada, and L. Chen B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function Blood, March 15, 2001; 97(6): 1809 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Kapsogeorgou, H. M. Moutsopoulos, and M. N. Manoussakis Functional Expression of a Costimulatory B7.2 (CD86) Protein on Human Salivary Gland Epithelial Cells that Interacts with the CD28 Receptor, but Has Reduced Binding to CTLA4 J. Immunol., March 1, 2001; 166(5): 3107 - 3113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maeda, M. Towatari, H. Kosugi, and H. Saito Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood, December 1, 2000; 96(12): 3847 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rohrbach, B. Gerstmayer, M. Biburger, and W. Wels Construction and Characterization of Bispecific Costimulatory Molecules Containing a Minimized CD86 (B7-2) Domain and Single-Chain Antibody Fragments for Tumor Targeting Clin. Cancer Res., November 1, 2000; 6(11): 4314 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. van Broekhoven, C. R. Parish, G. Vassiliou, and J. G. Altin Engrafting Costimulator Molecules onto Tumor Cell Surfaces with Chelator Lipids: A Potentially Convenient Approach in Cancer Vaccine Development J. Immunol., March 1, 2000; 164(5): 2433 - 2443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martin-Fontecha, M. Moro, M. C. Crosti, F. Veglia, G. Casorati, and P. Dellabona Vaccination with Mouse Mammary Adenocarcinoma Cells Coexpressing B7-1 (CD80) and B7-2 (CD86) Discloses the Dominant Effect of B7-1 in the Induction of Antitumor Immunity J. Immunol., January 15, 2000; 164(2): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Beissert, J. A. Bluestone, I. Mindt, M. Voskort, D. Metze, A. Mehling, T. A. Luger, T. Schwarz, and S. Grabbe Reduced Ultraviolet-Induced Carcinogenesis in Mice with a Functional Disruption in B7-Mediated Costimulation J. Immunol., December 15, 1999; 163(12): 6725 - 6731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sturmhoefel, K. Lee, G. S. Gray, J. Thomas, R. Zollner, M. O'Toole, H. Swiniarski, A. Dorner, and S. F. Wolf Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant Cancer Res., October 1, 1999; 59(19): 4964 - 4972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moro, A. M. Gasparri, S. Pagano, M. Bellone, P. Tornaghi, F. Veglia, A. Corti, G. Casorati, and P. Dellabona Induction of Therapeutic T-Cell Immunity by Tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules Cancer Res., June 1, 1999; 59(11): 2650 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Martin, J. G. Frelinger, and J. P.-Y. Ting Combination Gene Therapy with CD86 and the MHC Class II Transactivator in the Control of Lung Tumor Growth J. Immunol., June 1, 1999; 162(11): 6663 - 6670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mullins, C. J. Burger, and K. D. Elgert Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide J. Immunol., June 1, 1999; 162(11): 6811 - 6818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stremmel, E.A. Greenfield, E. Howard, G.J. Freeman, and V.K. Kuchroo B7-2 Expressed on EL4 Lymphoma Suppresses Antitumor Immunity by an Interleukin 4-dependent Mechanism J. Exp. Med., March 15, 1999; 189(6): 919 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. La Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Importance of B7-1-Expressing Host Antigen-Presenting Cells for the Eradication of B7-2 Transfected P815 Tumor Cells J. Immunol., December 15, 1998; 161(12): 6552 - 6558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nakajima, T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S.-i. Yoshino, H. Yagita, and K. Okumura Antitumor Effect of CD40 Ligand: Elicitation of Local and Systemic Antitumor Responses by IL-12 and B7 J. Immunol., August 15, 1998; 161(4): 1901 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bour, C. Horvath, C. Lurquin, J.-C. Cerottini, and H. R. MacDonald Differential Requirement for CD4 Help in the Development of an Antigen-Specific CD8+ T Cell Response Depending on the Route of Immunization J. Immunol., June 1, 1998; 160(11): 5522 - 5529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zheng, Y. Wu, Y. Guo, C. Lee, and Y. Liu B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge PNAS, May 26, 1998; 95(11): 6284 - 6289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. R. Emtage, Y. Wan, J. L. Bramson, F. L. Graham, and J. Gauldie A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model J. Immunol., March 1, 1998; 160(5): 2531 - 2538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Goedegebuure and T. J. Eberlein Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors Oncologist, October 1, 1997; 2(5): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
